KDM2B (also known as FBXL10) controls stem cell self-renewal, somatic cell reprogramming and senescence, and tumorigenesis. KDM2B contains multiple functional domains, including a JmjC domain that catalyzes H3K36 demethylation and a CxxC zinc-finger that recognizes CpG islands and recruits the polycomb repressive complex 1. Here, we report that KDM2B, via its F-box domain, functions as a subunit of the CUL1-RING ubiquitin ligase (CRL1/SCF KDM2B ) complex. KDM2B targets c-Fos for polyubiquitylation and regulates c-Fos protein levels. Unlike the phosphorylation of other SCF (SKP1-CUL1-F-box)/CRL1 substrates that promotes substrates binding to F-box, epidermal growth factor (EGF)-induced c-Fos S374 phosphorylation dissociates c-Fos from KDM2B and stabilizes c-Fos protein. Non-phosphorylatable and phosphomimetic mutations at S374 result in c-Fos protein which cannot be induced by EGF or accumulates constitutively and lead to decreased or increased cell proliferation, respectively. Multiple tumor-derived KDM2B mutations impaired the function of KDM2B to target c-Fos degradation and to suppress cell proliferation. These results reveal a novel function of KDM2B in the negative regulation of cell proliferation by assembling an E3 ligase to targeting c-Fos protein degradation that is antagonized by mitogenic stimulations.
INTRODUCTION
The activator protein-1 (AP-1) transcriptional factor complex is central to many biological processes.
1,2 Activator protein-1 complexes perform such diverse functions by potentially forming a large number of homo-or heterodimeric complexes through combinatorial interaction between members of Fos, Jun, ATF (activating transcription factor) and MAF (musculoaponeurotic fibrosarcoma) protein families. Proto-oncogene c-Fos is one of the first genes identified to be induced by mitogenic stimulation. 3 c-Fos forms a dimeric complex with c-Jun as the first identified activator protein-1. [4] [5] [6] [7] The regulation of c-Fos has been extensively studied and serves as paradigm for the tight, dynamic and multiple level regulation of stress and growth factor response. 8 c-Fos is typically expressed at a very low level in both cells cultured in vitro and in vivo. Mitogenic stimulation, particularly the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, rapidly induces c-Fos mRNA. 9, 10 The c-Fos protein is intrinsically unstable because of degradation by the 26S proteasome and is protected by phosphorylation. 11, 12 Multiple putative phosphorylation sites, mostly in the C-terminal region of the c-Fos protein, have been reported to regulate c-Fos protein stability. In particular, two residues-Ser362 and Ser374-were found to be phosphorylated by RSK1/2 and ERK1/2, respectively, 13 and their phosphorylation stabilizes c-Fos protein. 11 Genetic studies using knock-in mutation demonstrated that phosphorylation on these two residues have important roles for cell differentiation, cytokine response and tumorigenesis in vitro.
14 In contrast, the identity of the E3 ubiquitin ligase that targets c-Fos degradation and that antagonized by ERK1/2-mediated phosphorylation has not been established. UBR1, a member of the N-end rule family E3 ligase, has been linked to c-Fos degradation in the cytoplasm, which is protected by ERK5-mediated phosphorylation at two separate sites, Thr232, which blocks c-Fos nuclear export, and Ser32, which disrupts the interaction between c-Fos and UBR1. 15 The physiological significance of ERK5-mediated protection of c-Fos from UBR1-promoted degradation is currently unclear.
16
KDM2B (also known as FBXL10, NDY1, JHDM1B and CxxC2) controls stem cell self-renewal, 17 somatic cell reprogramming, 18 cell senescence 19, 20 and tumorigenesis. [21] [22] [23] KDM2B/FBXL10 is a protein of multidomains, including a JmjC domain situated at the N-terminal region of the protein, followed by a CxxC domain, a PHD domain, a F-box motif and seven leucine-rich repeats (LRRs, see Supplementary Figure S2A ). The JmjC domain catalyzes H3K36 demethylation 24 and the CxxC zinc-finger domain recognizes CpG islands and recruits polycomb repressive complex 1 (PRC1) to target genes. 17, [25] [26] [27] [28] KDM2B was also found to interact with SKP1 via its F-box domain, 27 ,28 a linker protein involved in the assembly of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, raising the possibility that KDM2B could additionally contain an E3 ligase function. The substrate of this putative KDM2B E3 ligase, however, has not been identified. Intriguingly, KDM2B has been reported to repress the transcription mediated by either c-Jun or c-Fos through a mechanism not completely understood. 14, 28 In this study, we explore the possibility that a KDM2B-containing E3 ligase targets c-Fos for ubiquitination and degradation.
RESULTS

KDM2B/FBXL10 and CUL1 destabilize c-Fos protein
To determine whether KDM2B regulates c-Fos protein level, as well as its transcription, we first generated HEK293 cells with stable knockdown of KDM2B. KDM2B expresses multiple isoforms produced by alternative splicing and differential transcriptional initiation. KDM2B-1 (NM_032590) is the longest and likely the fulllength isoform and carries the histone demethylase JmjC domain, whereas KDM2B-2 (NM_013910) is translated from an mRNA initiated at an internal promoter of the KDM2B-1 transcript and lacks the JmjC domain (Supplementary Figure S1A) . We first determined the subcellular localization and found that both long and short isoforms of KDM2B localized in the nucleus (Supplementary Figure S1B) . We then characterized three short hairpin RNAs (shRNAs) targeting different regions of KDM2B. We found that shKDM2B no. 1 targeted KDM2B-1 (slow-migrating) only and shKDM2B no. 2 targeted both of KDM2B-1 and KDM2B-2 effectively (Figure 1a) . Notably, we found an increase of c-Fos protein levels in cells stably expressing shKDM2B no. 1 and an even more marked increase of c-Fos protein levels in cells stably expressing shKDM2B no. 2. This result suggested that KDM2B negatively regulated c-Fos protein level and this function of KDM2B did not require its JmjC domain-encoded histone demethylase activity. We next examined whether KDM2B controls the stability of c-Fos protein. Owing to the extremely low basal level expression of c-Fos protein in unstimulated cells, we established HEK293 cells stably expressing FLAG-tagged c-Fos (Supplementary Figure S1C) . FLAG-c-Fos has a half-life (t 1/2 ) of 18 min (Supplementary Figure S1D) , confirming that c-Fos is a very short-lived protein undergoing rapid turnover. Treatment of cells with MG132, a 26S proteasome inhibitor, effectively blocked c-Fos degradation (Supplementary Figures S1E and S1F), confirming previous reports that c-Fos is degraded by the proteasome pathway. 11, 12 Importantly, knockdown of KDM2B effectively stabilized FLAG-c-Fos, extending its half-life from 18 min beyond 40 min of experimental duration (Figure 1b) .
To determine the mechanism by which KDM2B negatively regulates c-Fos, we tested the possibility that KDM2B promotes c-Fos degradation by binding to SKP1 and CUL1 through its F-box. We first determined whether CUL1 affects c-Fos protein level. We found that knockdown of CUL1 in HEK293 cells with two different small interference RNAs (siRNAs) resulted in an~6-fold increase of c-Fos protein levels without significant change in c-Fos mRNA levels ( Figure 1c ). Similarly depletion of KDM2B or CUL1 in normal human fibroblast strains 1 (NHF1) also resulted in the accumulation of c-Fos (Figure 1d ). Furthermore, codepletion of both KDM2B and CUL1 did not cause any additional increase of c-Fos protein level (Figure 1d ), suggesting that KDM2B and CUL1 act in the same pathway for controlling c-Fos. Taken together, these results demonstrate that KDM2B has a major role to target c-Fos protein degradation by a CUL1-based E3 ligase. Following commonly accepted nomenclature, we refer to the KDM2B-CUL1 E3 ligase as SCF/CRL1 KDM2B where the substrate recruiter F-box protein KDM2B is in superscript.
c-Fos is a substrate of SCF KDM2B/FBXL10 E3 ubiquitin ligase
To demonstrate that KDM2B assembles the SCF KDM2B ligase complex to target c-Fos ubiquitylation, we examined its interaction with endogenous SCF E3 ligase complex components. Co-immunoprecipitation (Co-IP) assays demonstrated that FLAG-tagged KDM2B interacted with endogenous SKP1, CUL1 and ROC1 (Figure 2a) . Meanwhile, we also detected the interaction between FLAG-KDM2B and endogenous c-Fos (Figure 2a) . The F-box domain in F-box proteins is essential for its binding to SKP1 and thus the assembly of SCF complex. [29] [30] [31] To determine the CUL1/SKP1-binding region in KDM2B, we constructed various deletion mutants of KDM2B (Supplementary Figure S2A) . Co-IP assays revealed that deletion of both LRRs and F-box domains from KDM2B (ΔLRF), but not the LRRs only (ΔLRR), completely disrupted its binding to CUL1 (Supplementary Figure S2B) . Conversely, the C-terminal of KDM2B (C300) containing the F-box and LRRs strongly interacted with CUL1 (Supplementary Figure S2B) , suggesting that the F-box domain of KDM2B is essential for its binding to CUL1. Structural analysis has previously shown that the N-terminal region of F-box domain in SKP2 is essential for its binding to SKP1. 32 Similar to SKP2, deletion of 23 amino acids in the N-terminal half of the F-box domain from KDM2B (residues 1056-1078, referred to as ΔF23) substantially reduced its binding to CUL1, and deletion of 48 residues containing the entire F-box domain (residues 1057-1105, ΔF48) completely abolished its binding to CUL1 (Figure 2b) . Two hydrophobic helical surfaces in the N-terminal tip of CUL1, H2 and H5, pack with hydrophobic and polar residues from SKP1 to form a large interface. 32 Mutation of either helix in CUL1 significantly disrupted its binding to KDM2B (Figure 2c ). Taken together, these results demonstrate that KDM2B, via its F-box domain, assembles a bona fide SCF-type E3 ubiquitin ligase complex.
To demonstrate that endogenously expressed c-Fos binds to KDM2B in vivo, HEK293 cells were treated with MG132 followed by immunoprecipitation using an antibody against c-Fos. The interactions between c-Fos and KDM2B, two isoforms translated by different promoters, were readily detected ( Figure 2d and Supplementary Figure S2C) . A fragment containing the C-terminal 300 residues of KDM2B that includes the LRRs and F-box could bind c-Fos, and conversely, deletion of the LRRs substantially reduced the binding of KDM2B with c-Fos (Supplementary Figure  S2D) . Deletion of the F-box from KDM2B (ΔF48) also reduced the interaction between KDM2B and c-Fos (Figure 2e ). These results indicate that the LRRs domain in KDM2B is mainly responsible for the binding with the substrate c-Fos and that the F-box domain may also contribute to the binding.
To demonstrate the ubiquitylation of c-Fos by the SCF KDM2B E3 ligase, we carried out both in vivo and in vitro ubiquitylation assays. We first knocked down either CUL1 or KDM2B and found that knocking down either gene reduced the ubiquitylation of endogenous c-Fos (Figure 2f ). An in vitro ubiquitylation assay demonstrated that the CUL1 E3 immunocomplexes efficiently ubiquitylated c-Fos, converting nearly all c-Fos into ubiquitylated form (Figure 2g ). The ubiquitylation of c-Fos was dependent on the addition of E1 and E2, CUL1 E3 complex, substrate receptor KDM2B and substrate c-Fos. We therefore conclude that c-Fos is a substrate of SCF KDM2B E3 ubiquitin ligase.
EGF stabilizes c-Fos by dissociating c-Fos from KDM2B/FBXL10 The MEK/ERK signaling pathway activates c-Fos transcription in response to extracellular growth factors such as EGF. 9 Supporting this conclusion, EGF stimulation markedly increased the endogenous c-Fos protein as early as within 20 min, which was compromised by the classical MEK1/2 (the ERK1/2-activating kinases) inhibitor U0126 (Supplementary Figures S3A-C) . In addition to the transcriptional activation, MEK/ERK pathway has also been reported to increase c-Fos level by stabilizing c-Fos protein through an undefined mechanism that involves phosphorylation at Ser362 and Ser374. 11 We therefore examined whether EGF stabilizes discrete slower migrating band (Figures 3a-d) , supporting a previous notion that the phosphorylated form c-Fos is resistant to the degradation.
To determine whether KDM2B is involved in the regulation of c-Fos by EGF, we first examined the effect of KDM2B knockdown on EGF-induced c-Fos protein levels and found that knockdown of KDM2B prolonged the high level of c-Fos protein following EGF stimulation ( Figure 3e ). To determine how EGF stabilizes c-Fos, we next examined the association between c-Fos and KDM2B in EGF-treated cells and found that EGF treatment dissociated their binding in a time-dependent manner ( Figure 3f ). The reduction of c-Fos and KDM2B interaction by EGF was completely blocked by U0126 (Figure 3g ), a highly selective inhibitor of both MEK1 and MEK2, suggesting the involvement of MEK/ERK signaling pathway in the regulation of c-Fos association with KDM2B. TPA (12-O-tetradecanoylphorbol-13-acetate) is a potent tumor promoter that activates PKC signaling pathway (PKC-Ras-Raf-MEK-ERK), which causes phosphorylation of c-Fos and dissociates c-Fos from KDM2B. Consistently, we found that TPA treatment decreased the association of KDM2B with c-Fos (Supplementary Figure S3F) and accumulated c-Fos protein (Supplementary Figure S3D) . Importantly, we found that knockdown of KDM2B stabilized c-Fos protein in the presence of TPA (Supplementary Figure S3E) . Taken together, these results demonstrate that c-Fos level is regulated at both transcriptional and post-translational levels and that c-Fos protein is stabilized by EGF-promoted phosphorylation, which dissociates c-Fos from its E3 ligase, KDM2B.
EGF-mediated phosphorylation at S374 stabilizes c-Fos and promotes cell proliferation It has been previously reported that c-Fos can be stabilized by phosphorylation at several sites, including S32, S362 and S374 sites, 11, 15 which are stimulated by ERK5 and ERK1/2 pathways. To determine which of these sites is involved in the ubiquitylation of c-Fos by the SCF KDM2B E3 ligase, we established HEK293 cells stably expressing FLAG-c-Fos mutants targeting individual serine residues. We found that a non-phosphorylatable mutation at S374 (S374A) completely abolished EGF-induced c-Fos stabilization and protein accumulation, whereas S362A and S32A mutations had mild or no effect on EGF-induced increase of c-Fos stability and steady-state c-Fos level (Figure 4a and Supplementary Figure S4A) . In contrast to S374A mutation, a phosphomimetic mutation of S374 (S374D) markedly extended the half-life of FLAG-c-Fos from 18 min to more than 1 h of the experimental duration (Figure 4b ), whereas neither S32D nor S362D mutation had significant effect on c-Fos stability (Supplementary Figure S4B) . Collectively, these results indicate that S374 is a major phosphorylation site that contributes to c-Fos stabilization in response to EGF stimulation.
We next determined whether EGF-promoted c-Fos dissociation from KDM2B is mediated by S374 phosphorylation. Western blot showed that the S374-phosphorylated form is closely associated with the appearance of the slow-migrating form of c-Fos in EGF-treated cells that are resistant to KDM2B binding (Figures 3a and e and Supplementary Figure S3A) . We then expressed wild-type and S374A mutant c-Fos and found that S374A mutation inhibited EGF-induced dissociation of c-Fos from KDM2B ( Figure 4c) . Notably, S374-phosphorylated c-Fos, while significantly induced by EGF, was not detected in the KDM2B immunocomplex (Figure 4d ). Consistently, S374D mutation of c-Fos reduced its binding to KDM2B (Figure 4e ). EGF-induced cell proliferation was partially compromised by the expression of S374A mutant of c-Fos and promoted by S374D mutation (Figures 4f and g ). Consistently, c-Fos S374D mutant that is resistant to KDM2B-mediated degradation is more potent than wild-type in activating target genes (Supplementary Figure S4C) . Taken together, these results demonstrate that EGF-induced phosphorylation at S374 in c-Fos disassociates it from KDM2B, resulting in increased stability and level of c-Fos and contributing to cell proliferation.
KDM2B/FBXL10 inhibits cell proliferation via promoting c-Fos degradation To determine the effect of KDM2B on cell proliferation, we first generated HeLa cells with stable knockdown of KDM2B, which resulted in increased c-Fos protein levels (Figure 5a, left panel) . Reintroduction of wild-type, but not ΔF-box mutant (ΔF48), KDM2B reduced the c-Fos protein level back to that similar in the parental HeLa cells (Figure 5a , right panel). Consistent with the increased level of c-Fos protein, ectopic expression of ΔF-box mutant, but not the wild-type KDM2B, increased the rate of cell proliferation, and this effect was not seen when c-Fos was knocked down (Figure 5b ). EdU (5-ethynyl-2′-deoxyuridine) cell proliferation assay also showed that KDM2B ΔF-box mutant lost its ability to suppress cell proliferation and knockdown of c-Fos reduced cell proliferation back to the rate similar to that seen in control cells (Figure 5c and Supplementary Figure S5) . We also examined several target genes of c-Fos linked to cell proliferation and growth, including cyclin D1 (CCND1) involved in G1 cell cycle control, matrix metallopeptidase 1 (MMP1) linked to embryonic development and tissue remodeling and CD44 linked to cell-cell interactions, cell adhesion and migration. We found that the accumulation of c-Fos resulting from reduced expression or dysfunction of KDM2B increased the transcriptional level of these genes (Figure 5d ). Taken together, these results demonstrate that KDM2B-promoted c-Fos degradation contributes to its function in the negative regulation of cell proliferation.
Tumor-derived mutations impair the function of KDM2B/FBXL10 to target c-Fos degradation and suppress cell proliferation Recent cancer genome sequencing efforts have identified a number of mutations targeting KDM2B. For example, the COSMIC (Catalog of Somatic Mutations in Cancer) database reports 16 deletions and 7 nonsense mutations of KDM2B in different type of human cancers (Supplementary Figure S6) . A loss of function of KDM2B could be viewed consistent with its function in suppressing cell proliferation. Among these reported mutations are three, C1085fs*14, W1161*, H1297fs*4, that predict to destroy the F-box or/and the leucine-rich repeats (LRRs) domains of KDM2B Purified c-Fos protein was incubated with immunopurified E3 CUL1 complex and KDM2B individually or in combination in the presence or absence of E1, E2, ATP and FLAGubiquitin in vitro for 1 h. The reaction mixture was resolved by SDS-PAGE and blotted using antibodies (from top to bottom panels) recognizing FLAG, HA and MYC. (Figure 6a ). We therefore set to determine whether these tumorderived mutations affect the activity of KDM2B in promoting c-Fos degradation and suppressing cell proliferation. We recreated all these three mutations and first examined their effect on the binding of KDM2B with c-Fos. We found that all three mutations reduced the binding of KDM2B with c-Fos when compared with the wild-type KDM2B expressed at a similar level (Figure 6b ). We next carried out in vivo ubiquitylation assay and demonstrated that all three tumor-derived mutations in KDM2B evidently reduced the activity of KDM2B in promoting c-Fos ubiquitylation (Figure 6c) . Knockdown-replacement experiment demonstrated that these three mutations also abolished the ability to decrease c-Fos protein (Figure 6d) . We further demonstrated that all three tumor-derived mutants lost the function of KDM2B in suppressing cell proliferation (Figure 6e ). Taken together, these results identify the first functional consequence linked to the tumor mutations in KDM2B.
DISCUSSION
This paper reports two key findings. First, KDM2B/FBXL10 functions as a bona fide F-box protein and assembles into an activate SCF/CRL1-type E3 ubiquitin ligase. KDM2B contains a JmjC domain that catalyzes histone H3K36 demethylation. Our finding identifies a second enzymatic activity to this multidomain protein.
Of 32 human histone demethylases proteins, KDM2B, and its closest homolog, KDM2A/FBXL11, are the only two KDMs that contain an F-box domain. The F-box domains encode by KDM2B and KDM2A are highly related (78%). Our results suggest that KDM2A, which, similar to KDM2B, also catalyzes H3K36 demethylation and recognizes CpG through its JmjC and CxxC domains, 33 is likely to form a functional SCF E3 ligase. It remains to be determined whether and how these two enzymatic activities are mechanistically linked in gene regulation. It will also be interesting to determine whether KDM2B catalyzes ubiquitylation of any subunit of polycomb repressive complex 1 complex or a histone.
Second, c-Fos is robustly ubiquitylated and degraded by SCF KDM2B E3 ligase. As an immediate-early gene, c-Fos level is rapidly accumulated by both transcriptional activation and protein stabilization, thereby conferring cells the ability to regulate rapidly activator protein-1 target genes during stress and mitogenic responses. Our finding provides a mechanism-dissociating c-Fos from its E3 ligase by EGF-promoted phosphorylation at S374-for cells to stabilize c-Fos protein in response to mitogenic stimulation. Our observations also provide a plausible explanation for the previously observed inhibition of c-Jun-and c-Fos-mediated transcriptional activity by KDM2B. 14, 28 Conversely, this mechanism allows cells to maintain the c-Fos at a very low level after withdrawal of the mitogenic stimulation through turning off the c-Fos transcription and constitutive degradation of c-Fos protein once the S374 is dephosphorylated. Many other SCF substrates are also regulated by phosphorylation, which targets a small motif, known as degron, and promotes the substrate to bind with an F-box protein and be degraded by the SCF ligase. Linking signaldependent phosphorylation to ubiquitylation provides cells an efficient mechanism to regulate protein function through crosstalk between different post-translational modifications. The finding reported here further expands the spectrum of this crosstalk.
MATERIALS AND METHODS
Plasmids and chemicals
Full-length human KDM2B cDNA was a kind gift from Michele Pagano of New York University (New York, NY, USA). Wild-type and mutant KDM2B were constructed into pRK7-N-FLAG vector for transient expression or pQCXIH-N-FLAG vector for stable transduction by retrovirus infection. Wildtype and mutant CUL1 were constructed into pRK7-N-MYC vector for transient expression. c-Fos cDNA was amplified from a cDNA library of HEK293 cells. Wild-type and mutant c-Fos were constructed into pCDNA3-N-3HA vector for transient expression or pQCXIH-N-FLAG vector for stable transduction by retrovirus infection. The lentivirus packaging plasmids containing shKDM2B were purchased from Shanghai Genechem Company (Shanghai, China). The target sequences of shKDM2B are as follows: shKDM2B no. 1, 5′-TGAGCGTGAAAGGTTGTTT-3′; shKDM2B no. 2, 5′-GCC TTTACAAGAAGACATT-3′; shKDM2B no. 3, 5′-TTCTTCAAACGCTGTGGAA-3′. MG132 (C2211; Sigma-Aldrich, St Louis, MO, USA), CHX (94271; Amresco, Solon, OH, USA), EGF (AF-100-15; PeproTech, Rocky Hill, NJ, USA), U0126 (S1102; Selleckchem, Shanghai, China) and SCH772984 (S7101; Selleckchem) were purchased commercially.
Cell culture, transfection and proliferation assay HEK293, HEK293T and HeLa cells were purchased from the American Type Culture Collection (Manassas, VA, USA). NHF1 was a kind gift from Dr William K Kaufmann of University of North Carolina (Chapel Hill, NC, USA). NHF1 was derived from neonatal foreskins and established in secondary culture according to established methods. 34 Mycoplasma contamination was not detected by PCR. HEK293, HEK293T and HeLa cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% newborn calf serum, 8 mM L-glutamine, 50 μg/ml penicillin and streptomycin (Gibco, Grand Island, NY, USA). NHF1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. HEK293 and HeLa cells with stable knockdown or overexpression were established by lentivirus or retrovirus transduction, respectively, selected and maintained in medium containing 1 μg/ml puromycin or 50 μg/ml hygromycin B (Amresco). Cells were cultured in a 37°C incubator with 5% CO 2 . Cell transfection was performed using Lipofectamine 2000 (Life Technologies) for plasmid DNA or Lipofectamine RNAi MAX (Life Technologies) for siRNAs following the manufacturer's instructions. Cells were harvested at 48-72 h posttransfection for protein analyses.
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For cell proliferation assay, stable HEK293 cells were triply seeded in 6-well plates at a density of 2 × 10 5 cells per well and deprived of serum for indicated length of time after adhering for 12 h. Stable HeLa cells were triply seeded in 6-well plates at a density of 4 × 10 4 cells per well. Cell numbers were counted daily by using Countstar IC1000 (Alit International Trade Co., Ltd., Shanghai, China). For EdU cell proliferation assay, HeLa cells were labeled with 10 μM EdU for 1 h, and then collected with 1% bovine serum albumin in phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde in PBS. After incubation for 20 min, cells were washed with 1% bovine serum albumin in PBS and permeabilized in 0.5% Triton X-100 for 20 min. Cells were washed and resuspended in the cocktail (250 μl for each sample: PBS 215 μl, CuSO 4 10 μl, sodium ascorbate 25 μl and Azide Alexa Fluor (A10266; Life Technologies) 0.6 μl for 30 min. Cells were washed and resuspended in 500 μl 1% bovine serum albumin in PBS. The percentage of EdU-positive cells was determined by using BD ACCURI C6 Flow Cytometer (BD Biosciences, San Jose, CA, USA).
Antibodies and immunological procedures
Antibodies against FLAG (SG4110-16; Shanghai Genomics Technology, Shanghai, China), MYC (SG4110-18; Shanghai Genomics Technology), β-actin (A00702; GenScript, Shanghai, China), HA (sc-7392; Santa Cruz, Dallas, TX, USA), KDM2B (09-864; Millipore, Billerica, MA, USA), CUL1 (2436-1; Epitomics, Shanghai, China), SKP1 (2538-1; Epitomics), ROC1 (5296-1; Epitomics), ubiquitin (Z045801-5; Dako, Carpinteria, CA, USA), phospho-ERK1/2(Thr202/Tyr204) (4370S; Cell Signaling Technology, Shanghai, China), ERK1/2 (4695P; Cell Signaling Technology), c-Fos (3620-1 (Epitomics) and sc-52 (Santa Cruz)), phospho-c-Fos (Ser32) (5348S; Cell Signaling Technology) and phospho-c-Fos (Ser374) (sc-81485; Santa Cruz) were purchased commercially.
For immunoprecipitation experiments, cells were washed with cold PBS once and lysed in a NP-40 lysis buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 0.5% NP-40 and supplemented with protease inhibitors and phosphatase inhibitors) for 1 h at 4°C with gentle shaking. Ten percent of cell lysates were mixed directly with 5x Laemmli sample buffer and used as input on western blot. The rest were incubated with specific antibody for 3 h at 4°C, followed by the addition of protein A-conjugated beads for 1 h at 4°C. Immunoprecipitates were washed three times with lysis buffer, and proteins were eluted from beads with 50 μl 1x Laemmli loading buffer.
For western blotting, cells were washed with cold PBS once and lysed in 1x Laemmli loading buffer directly or in NP-40 buffer if used for a subsequent immunoprecipitation. Lysates were heated at 99°C for 5 min, and resolved on 8-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membrane. Membrane was blocked in 5% milk in Tris-buffered saline and Tween-20 for 1 h at room temperature, followed by incubation with a primary antibody overnight at 4°C, and a horseradish peroxidaseconjugated secondary antibody for 1 h at room temperature. The membrane was imaged either by a Typhoon Scanner (GE Healthcare, Lafayette, CO, USA) or a LAS 4000 Imager system (GE Healthcare).
In vivo and in vitro ubiquitination assay
The procedures for both assays were modified from our previously published report. 35 Briefly, for in vivo ubiquitylation assay, at 36-48 h after transfection, cells were treated with proteasome inhibitor, MG132 (20 μM) for 6 h to accumulate polyubiquinated c-Fos and thus increase the sensitivity of detection. Cells were collected and lysed in 1% SDS lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA and 1 mM DTT) and boiled for 10 min. For immunoprecipitation, the clarified SDS lysates were diluted 10-fold in 0.5% NP-40 lysis buffer, 10% of total lysates were mixed directly with 5x Laemmli sample buffer and used as input on western blot. The rest were incubated with anti-c-Fos antibody for 3 h at 4°C, followed by the addition of protein A-agarose for 1 h at 4°C. Immunoprecipitates were washed three times with lysis buffer and boiled in 1x Laemmli loading buffer before SDS-PAGE. The ubiquitylation levels of c-Fos were determined by immunoblot with anti-Ub antibody.
For in vitro ubiquitylation assay, plasmids expressing different genes, as indicated in the figures, were transfected into HEK293T cells. At 48 h after transfection, cells were lysed in NP-40 lysis buffer supplemented with a cocktail of protease inhibitors and phosphatase inhibitors, followed by immunoprecipitation using anti-c-MYC agarose (A7470; Sigma-Aldrich) or anti-HA Sepharose (sc-7392 AC; Santa Cruz). Immunocomplexes were washed with the lysis buffer three times and eluted with MYC (EQKLISEEDL) or HA (YPYDVPDYA) antigen peptides, respectively. 3HA-cFos protein was immunopurified and used as the substrate. CUL1-based E3 ligase complex and substrate receptor KDM2B were derived from HEK293T cells co-transfected with plasmids expressing MYC-CUL1, ROC1 and SKP1 or singularly transfected with plasmid expressing MYC-KDM2B, respectively. In vitro ubiquitylation was initiated by mixing the substrate with immunopurified E3 complex and KDM2B in a ubiquitin ligation buffer (50 mM Tris-HCl at pH 7.4, 5 mM MgCl 2 , 2 mM NaF, 2 mM ATP, 10 nM okadaic acid (Beyotime Biotechnology, Shanghai, China), 0.6 mM DTT, 12 μg of bovine ubiquitin (Sigma-Aldrich), 1 μg of FLAG-tagged ubiquitin (SigmaAldrich), 60 ng of E1 (E301; Boston Biochem, Cambridge, MA, USA), 500 ng of E2 (human Ubc5c), final volume: 30 μl). The reactions were incubated at 37°C for 1 h on a rotator with gentle shaking, then terminated with SDS sample buffer and boiled at 99°C for 5 min before SDS-PAGE. The ubiquitylation levels of c-Fos were determined by immunoblot with either anti-FLAG or anti-HA antibody.
RNA interference
RNAi-mediated downregulation of human KDM2B, CUL1, was performed by transfecting siRNAs into cells in accordance with the manufacturer's instructions of Lipofectamine RNAi MAX (Life Technologies). A nontargeting control siRNA duplex (sense, 5′-UUCUCCGAACGUGUCACGUTT-3′) was included as a negative control. The knockdown efficiency was assessed 72 h after transfection by western blot.
The siRNAs targeting KDM2B (siGENOME SMARTpool M-014930-01-0005) were purchased from Dharmacon (Lafayette, CO, USA), which was a mixture of four siKDM2B oligonucleotides. The siRNAs targeting CUL1 (Stealth siRNAs HSS112311 and HSS112310) were purchased from Life Technologies. The sequences of all siRNAs used in this study are shown as follows: siKDM2B no. 1, 5′-CAGCAUAGACGGCUUCUCU-3′; siKDM2B no. 2, 5′-GGGAGUCGAUGCUUAUUGA-3′; siKDM2B no. 3, 5′-GACCUCAGCUGGACC AAUA-3′; siKDM2B no. 4, 5′-GCAAUAAGGUCACUGAUCA-3′; siCUL1 no. 1, 5′-GGCCACUGAAUAAACAGGUAACAAA-3′; siCUL1 no. 2, 5′-GGAGCUCA GUUUGUUGGCCUGGAAU-3′; siFos, 5′-GGGAUAGCCUCUCUUACUA-3′. 
Statistical analysis
Statistical analyses were performed with a paired, two-tailed Student's ttest. All data shown represent the results obtained from triplicated independent experiments with standard errors of the mean (mean ± s.d.). The values of P o0.05 were considered statistically significant. No sample was excluded from the analysis.
